B7-33
Relaxin-family peptide analog
B7-33 is a synthetic peptide derived from a naturally occurring molecule called human relaxin-2, which is known for its powerful anti-fibrotic and tissue-protective properties. Unlike the full hormone, B7-33 is designed to target specific healing pathways without affecting blood pressure, making it safer for regular use. It works by activating a receptor called RXFP1, which helps reduce fibrosis (the buildup of scar tissue) in organs like the heart, lungs, liver, and kidneys.
By reducing fibrosis and inflammation, B7-33 may support healthier tissue repair and prevent long-term damage from chronic stress, aging, or injury. It's currently being studied for its potential to treat conditions like heart failure, pulmonary fibrosis, and liver disease. While still in early research stages, B7-33 shows promise as a regenerative therapy that helps the body heal more efficiently without the side effects of full relaxin-based drugs.
Protocols
1. Anti-Fibrotic Therapy (Heart, Lung, Kidney, Liver Fibrosis)
Dosage: 100–250 μg subcutaneously (SC) or intravenously (IV) daily
Cycle Duration: 6–8 weeks
Break Duration: 4 weeks off before resuming if necessary
Stacking: Often combined with KPV and TB-500 for enhanced tissue repair
Expected Benefits: Reduced fibrotic scarring, improved organ function, better tissue elasticity
2. Cardiovascular Protection & Heart Failure Support
Dosage: 250 μg SC or IV every other day
Cycle Duration: 6 weeks
Break Duration: 4 weeks off before resuming
Stacking: Works well with GHK-Cu for vascular health and BPC-157 for cardiac tissue healing
Expected Benefits: Improved blood vessel function, reduced hypertension-related damage, enhanced heart performance
3. Wound Healing & Post-Surgical Recovery
Dosage: 100–200 μg SC daily
Cycle Duration: 4 weeks
Break Duration: Not required for short-term use
Stacking: Best combined with BPC-157 and GHK-Cu for optimal wound healing and reduced scarring
Expected Benefits: Faster wound healing, reduced scar formation, improved tissue regeneration
Further reading
B7-33 was designed to provide the anti-fibrotic effects of Relaxin-2 without its significant vasodilatory effects, which can cause low blood pressure in some patients. The peptide’s primary action involves modulating TGF-β1 signaling, a major factor in fibrosis development. In preclinical studies, B7-33 has demonstrated significant reductions in collagen deposition in animal models of cardiac fibrosis, lung fibrosis, and kidney fibrosis, highlighting its potential for treating a range of fibrotic disorders.
One of the key advantages of B7-33 over full-length Relaxin-2 is its improved stability and specificity. Traditional Relaxin therapies have broader systemic effects, including vasodilation and hormonal modulation, which can limit their therapeutic use. By contrast, B7-33 selectively activates RXFP1 without causing significant cardiovascular side effects. This makes it a safer long-term option for conditions that require chronic fibrosis management.
Additionally, B7-33’s potential applications extend beyond fibrosis into areas such as regenerative medicine and post-surgical recovery. By reducing excessive scar tissue formation, this peptide could be useful for improving wound healing outcomes in surgery, trauma recovery, and even aesthetic medicine. As research continues, B7-33 may become a leading peptide therapy for managing fibrosis-related diseases and enhancing recovery processes in both clinical and performance settings.
References
- Samuel, C.S., et al. (2016). B7-33: A novel Relaxin-derived peptide with anti-fibrotic properties. Nature Communications, 7, 13342.
Chow, B.S.M., et al. (2015). Relaxin signaling in fibrosis reduction and cardiovascular health. Journal of Molecular Medicine, 93(8), 897-905.
Hewitson, T.D., et al. (2019). Targeting fibrosis: The role of Relaxin and its mimetics. Clinical Science, 133(10), 1221-1235.
Leo, C.H., et al. (2017). RXFP1 activation and its effects on vascular remodeling and endothelial function. Frontiers in Pharmacology, 8, 599.
Samuel, C.S., et al. (2014). The role of Relaxin peptides in wound healing and scar modulation. Matrix Biology, 38, 37-46.